Medication
Jamp Digoxin
DIN 02498510 · Jamp Pharma Corporation Likely a generic
What it is
- Active ingredients
- Digoxin — 0.125 mg
- Form and route
- Tablet · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2022-07-22
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $0.1030
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 0.125mg Tab and will substitute one for another at a pharmacy counter in Ontario.
- Auro-Digoxin 02554402Auro Pharma Inc
- PMS-Digoxin 02335719Pharmascience Inc
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Cardiovascular system
- ATC code
- C01AA05
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C01AA05, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Health Canada has published 2 recalls or safety alerts naming this product. Read them on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.
JAMP DIGOXIN: Affected lot may contain overweight or underweight tablets.
Health Canada says: If you are taking this medication, speak with your pharmacist as soon as possible. Your pharmacist will check if your product is affected and provide a replacement if needed. It may not be possible to know if you are getting the correct dose of digoxin by looking at the tablets. Overweight or underweight tablets may look like normal-sized tablets.Continue taking your JAMP Digoxin 0.0625 or 0.125 mg tablets until you speak with your pharmacist, as digoxin is an important drug when you have a heart condition.Contact a health care professional immediately if you or someone you are caring for experience serious side effects related to an overdose of digoxin or reduced efficacy of therapy.Contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at custjamp@jamppharma.com, if you have questions about this recall.Report any health product-related side effects or complaints to Health Canada.
Matched on the product name at the start of the notice.
Jamp Digoxin tablet: Over-sized tablet
Health Canada says: Return your JAMP Digoxin 0.0625 mg tablets to your pharmacy for replacement as soon as possible. Until you can return them, continue to take your JAMP Digoxin but do not take tablets that look oversized (see image, which shows an oversized tablet on the left and proper-sized tablet on the right). If you are unsure whether your product is affected, check with your pharmacy.Contact a health care professional immediately if you or someone you are caring for experience serious side effects.Contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at custjamp@jamppharma.com, if you have questions about this recall.Report any health product-related side effects or complaints to Health Canada.
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Jamp Digoxin → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.